INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 211 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2021. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,793,147 | -10.0% | 34,424 | +9.4% | 0.03% | -3.4% |
Q2 2023 | $1,991,730 | +10.0% | 31,455 | -6.0% | 0.03% | +3.6% |
Q1 2023 | $1,811,480 | +16.9% | 33,453 | +14.2% | 0.03% | +12.0% |
Q4 2022 | $1,550,185 | +9.3% | 29,293 | -3.9% | 0.02% | 0.0% |
Q3 2022 | $1,418,000 | +33.6% | 30,466 | +63.9% | 0.02% | +38.9% |
Q2 2022 | $1,061,000 | -27.1% | 18,589 | -21.8% | 0.02% | -14.3% |
Q1 2022 | $1,455,000 | +48.8% | 23,769 | +27.2% | 0.02% | +61.5% |
Q4 2021 | $978,000 | +63.5% | 18,681 | +16.5% | 0.01% | +44.4% |
Q3 2021 | $598,000 | – | 16,030 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |